For decades, the treatment of advanced prostate cancer was mainly based on the manipulation of the androgen receptor-controlled proliferation pathway. Chemotherapy only played an additional important role with the advent of taxanes. The progress in translational research in recent years has led to innovations in the therapeutic environment. With the decoding of the homologous repair deficiency (HRD) machinery and its ability to be influenced by PARP inhibitors, targeted therapies moved into the therapeutic focus for selected patients. The first positive phase III study for PARP inhibitors is already available. In addition, immunotherapy for the treatment of prostate cancer, which is now widely used in oncology, is also making progress; both checkpoint inhibitors and bispecific antibodies have shown clinically useful activities. Cellular therapies such as CAR T cells, which are directed against prostate-specific membrane antigen (PSMA), are still at an early stage of development. In this review, the authors provide a summary of the basic principles and clinical development of these new therapies.
Der Urologe. Ausg. A. 2020 Apr 17 [Epub ahead of print]
C Grüllich, E Nößner, D Pfister, V Grünwald
Onkologie und Hämatologie, Uniklinik-Dresden, Fetscherstr. 74, Haus 27, 01307, Dresden, Deutschland. ., Immunoanalytics- Research Group Tissue Control of Immunocytes, Helmholtz Zentrum München, München, Deutschland., Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln, Köln, Deutschland., Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung) und Klinik für Urologie, Universitätsklinikum Essen (AöR), Essen, Deutschland.